Perspective Therapeutics (CATX) Competitors $3.68 -0.16 (-4.17%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.72 +0.03 (+0.95%) As of 08/1/2025 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CATX vs. BLFS, TNDM, PLSE, MDXG, INMD, KMTS, SIBN, IRMD, EMBC, and BBNXShould you be buying Perspective Therapeutics stock or one of its competitors? The main competitors of Perspective Therapeutics include BioLife Solutions (BLFS), Tandem Diabetes Care (TNDM), Pulse Biosciences (PLSE), MiMedx Group (MDXG), InMode (INMD), Kestra Medical Technologies (KMTS), SiBone (SIBN), iRadimed (IRMD), Embecta (EMBC), and Beta Bionics (BBNX). These companies are all part of the "medical equipment" industry. Perspective Therapeutics vs. Its Competitors BioLife Solutions Tandem Diabetes Care Pulse Biosciences MiMedx Group InMode Kestra Medical Technologies SiBone iRadimed Embecta Beta Bionics BioLife Solutions (NASDAQ:BLFS) and Perspective Therapeutics (NYSE:CATX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation. Is BLFS or CATX more profitable? BioLife Solutions has a net margin of -11.81% compared to Perspective Therapeutics' net margin of -4,096.66%. BioLife Solutions' return on equity of -0.66% beat Perspective Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets BioLife Solutions-11.81% -0.66% -0.58% Perspective Therapeutics -4,096.66%-27.40%-23.16% Do institutionals and insiders believe in BLFS or CATX? 93.2% of BioLife Solutions shares are owned by institutional investors. Comparatively, 54.7% of Perspective Therapeutics shares are owned by institutional investors. 2.2% of BioLife Solutions shares are owned by insiders. Comparatively, 3.7% of Perspective Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate BLFS or CATX? BioLife Solutions currently has a consensus target price of $31.00, indicating a potential upside of 48.97%. Perspective Therapeutics has a consensus target price of $12.56, indicating a potential upside of 241.18%. Given Perspective Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Perspective Therapeutics is more favorable than BioLife Solutions.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLife Solutions 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Perspective Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.18 Which has higher valuation and earnings, BLFS or CATX? BioLife Solutions has higher revenue and earnings than Perspective Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioLife Solutions$87.76M11.34-$20.18M-$0.29-71.76Perspective TherapeuticsN/AN/A-$46.51MN/AN/A Does the media refer more to BLFS or CATX? In the previous week, BioLife Solutions had 1 more articles in the media than Perspective Therapeutics. MarketBeat recorded 3 mentions for BioLife Solutions and 2 mentions for Perspective Therapeutics. Perspective Therapeutics' average media sentiment score of 0.98 beat BioLife Solutions' score of 0.73 indicating that Perspective Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLife Solutions 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Perspective Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, BLFS or CATX? BioLife Solutions has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Comparatively, Perspective Therapeutics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. SummaryBioLife Solutions beats Perspective Therapeutics on 8 of the 13 factors compared between the two stocks. Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CATX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CATX vs. The Competition Export to ExcelMetricPerspective TherapeuticsSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$273.16M$65.78M$5.49B$20.65BDividend YieldN/AN/A4.73%3.67%P/E RatioN/A6.2128.7829.03Price / SalesN/A109.49372.2066.13Price / CashN/A18.4135.4522.84Price / Book1.387.368.274.43Net Income-$46.51M-$25.86M$3.25B$994.22M7 Day Performance-9.36%-5.86%-3.70%-3.39%1 Month Performance8.55%3.71%4.34%-2.09%1 Year Performance-70.06%47.43%25.90%10.09% Perspective Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CATXPerspective Therapeutics2.3993 of 5 stars$3.68-4.2%$12.56+241.2%-72.5%$273.16MN/A0.0070News CoverageBLFSBioLife Solutions2.8094 of 5 stars$22.23-1.6%$31.00+39.5%-10.9%$1.08B$82.25M-76.65440Positive NewsUpcoming EarningsTNDMTandem Diabetes Care3.5041 of 5 stars$16.84+6.0%$32.71+94.3%-56.3%$1.06B$940.20M-6.062,650Positive NewsUpcoming EarningsPLSEPulse Biosciences3.9326 of 5 stars$15.21+1.9%$22.00+44.6%-2.3%$1.00B$700K0.00140News CoveragePositive NewsMDXGMiMedx Group3.1093 of 5 stars$6.79+0.3%$11.50+69.4%+7.2%$999.94M$348.88M25.15870Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionINMDInMode3.1262 of 5 stars$14.54-1.2%$18.54+27.5%-17.1%$930.44M$394.82M6.24480News CoverageEarnings ReportAnalyst ForecastKMTSKestra Medical Technologies0.9976 of 5 stars$16.50-0.3%$27.33+65.7%N/A$849.82M$59.81M0.00300Positive NewsSIBNSiBone3.7055 of 5 stars$17.60+2.0%$22.50+27.8%+17.2%$735.10M$167.18M-27.50350Positive NewsUpcoming EarningsIRMDiRadimed4.1846 of 5 stars$57.11+1.4%$72.00+26.1%+43.4%$716.11M$73.24M36.85110Trending NewsEarnings ReportDividend AnnouncementGap UpEMBCEmbecta4.6458 of 5 stars$11.33-3.4%$19.00+67.7%-35.3%$685.53M$1.12B12.592,100News CoverageUpcoming EarningsBBNXBeta Bionics2.3503 of 5 stars$13.99-5.7%$23.44+67.6%N/A$643.41M$65.12M0.00294Trending NewsEarnings ReportAnalyst ForecastLockup ExpirationAnalyst Revision Related Companies and Tools Related Companies BLFS Alternatives TNDM Alternatives PLSE Alternatives MDXG Alternatives INMD Alternatives KMTS Alternatives SIBN Alternatives IRMD Alternatives EMBC Alternatives BBNX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CATX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CATX Stock Alerts